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Transmissible spongiform encephalopathies (TSE) are
fatal neurodegenerative diseases of humans and ani-
mals. The underlying infectious agent, the prion, accu-
mulates not only in the central nervous system (CNS)
but also in secondary lymphoid organs. This review re-
visits the role of the immune system in peripheral prion
pathogenesis while focusing on the mechanisms by
which extraneural and extralymphatic prion infectivity
develops. Interestingly, the same proinflammatory cyto-
kines and homeostatic chemokines that are involved
in lymphoid neogenesis and compartmentalization of
immune cells appear to represent the crucial molecular
switches responsible for the establishment of extraneu-
ral prion reservoirs.
Prion diseases continue to be inexorably fatal, and
no therapy other than palliation is available. On the
other hand, prion infections represent a fascinating bio-
logical phenomenon, which has elicited a tremendous
interdisciplinary research effort at the interface be-
tween neuroscience and immunology. It has long been
known that prions not only invade the CNS but also
colonize the lymphoid compartment of infected individ-
uals. This finding raises a number of intriguing ques-
tions concerning the interface between prions and the
immune system. Some of the most inspiring results
have been obtained by studying prion pathogenesis in
mice whose lymphoid organogenesis was manipulated
by genetic or pharmacological means.
Significant titers of prion infectivity can be detected
in the lymphoreticular system (LRS) in most transmissi-
ble spongiform encephalopathies (TSEs). However, the
extent of involvement is variable and depends on the
tropism of specific prion strains and also on ill-defined
host factors (Aguzzi and Sigurdson, 2004). In many in-
stances prion infectivity is detected in the LRS before
it arises in the CNS. LRS-associated prion infectivity, or
proteinase K (PK)-resistant prion protein (termed PrPSc),
was found in human patients suffering from variant and
sporadic Creutzfeldt-Jakob disease (vCJD or sCJD),
scrapie-affected sheep and goats, terminally BSE-sick
cattle, as well as elk and deer suffering from chronic
wasting disease (CWD) (Aguzzi and Polymenidou, 2004;
Bruce et al., 2001; Glatzel et al., 2003; Mabbott and
Bruce, 2003; Sigurdson et al., 2002). However, many
fundamental questions regarding the tropism of prions
for lymphoid tissues remain unanswered. Also, the
mechanisms by which prions are transported from the
site of prion replication to peripheral nerves are un-*Correspondence: adriano@pathol.unizh.chknown (Aguzzi and Heikenwalder, 2003; Mabbott et al.,
1998; Weissmann et al., 2001).
In the central nervous system (CNS), prion infections
cause characteristic neuropathological lesions with spon-
giform vacuolation, accumulation of abnormally folded
PrPC, designated PrPSc, and neuronal cell loss in the
CNS accompanied by proliferation of astrocytes. Prion
pathology also includes the brain’s intrinsic macrophages,
with large-scale activation and proliferation of micro-
glial cells. One essential requirement for prion patho-
genesis has been established beyond all reasonable
doubt: if prions multiply by imparting their conforma-
tion onto normal cellular host-encoded prion protein
(PrPC), organisms devoid of PrPC should be resistant to
scrapie. Indeed, lack of the Prnp gene confers absolute
resistance against intracerebral and peripheral scrapie
infection (Büeler et al., 1993). PrPC is essential for neu-
ronal damage in infected individuals (Brandner et al.,
1996; Mallucci et al., 2003). Quite surprisingly, high
prion titers in lymphoid organs are not accompanied by
significant histopathological changes (Clarke and Haig,
1971; Dickinson et al., 1972), although murine scrapie
infection was recently reported to cause an abnormal
germinal center reaction in the spleen (McGovern et
al., 2004).
The Early Days of Prion Immunology
Genetic asplenia or splenectomy of mice prior or shortly
after peripheral prion challenge significantly prolongs the
life span of scrapie-infected mice, whereas thymectomy
or genetic athymia has no effect (Clarke and Haig,
1971). Splenectomy after intraperitoneal (i.p.) prion in-
oculation at various time points has revealed that pe-
ripheral prion pathogenesis becomes independent of the
spleen once it has reached the spinal cord (Kimberlin
and Walker, 1989). However, a splenic replication phase
is not obligatory in all rodent TSE models (Kimberlin
and Walker, 1986). For example, Tateishi and coworkers
have found no effect of splenectomy on incubation
times for the Fukuoka-1 strain, a mouse-adapted CJD
prion (Manuelidis et al., 1978; Mohri et al., 1987). This
is one of several hints that the various prion strains ap-
pear to differ in their tissue tropisms (Aguzzi, 2004).
Before the invention of fluorescence-activated cell sort-
ing, the cellular distribution of prions in the LRS was
studied by separation of lymphocyte cells into various
subpopulations based on buoyant density of different
adherence of cells to plastic (Lavelle et al., 1972). In
these early experiments, it was reported that cells with
relatively high specific infectivity had a density charac-
teristic of lymphoblasts, myeloblasts, and macrophages.
Enrichment of macrophages did not enhance scrapie
infectivity. Already in these relatively crude fractionation
attempts it became clear that the stroma contained
w10 times more prion infectivity than the pulp (Clarke
and Kimberlin, 1984). Furthermore, sublethal doses of γ
irradiation, affecting mitotically active hematopoietic cells
(but not resident postmitotic cells), administered as a
single dose or fractionated dose before or after inocula-
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146Figure 1. Necessity of LT Signaling in Lymphoid Organ Development, Maintenance of Lymphoid Microarchitecture, and Prion Replication
(A) LTα1β2-expressing CD3−CD4+CD45+ cells bind vascular adhesion molecule 1 (VCAM-1)+ stromal cells through activated α4β1 integrin.
This binding ensures LTßR engagement of stromal cells, and induces the production of homeostatic chemokines CCL19, CCL21, CXCL12
and CXCL13, driving lymphoid organogenesis and upregulation of VCAM-1.
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147virus entry site mediator (HVEM) (Browning et al., 1995,compartment is the essential mediator of prion inva-
(B) Cell cluster formation through hematopoietic cells, in contact with various stromal cells, allows transdifferentiation of CD3−CD4−CD45+
cells toward CD3−CD4+CD45+. This leads to subsequent upregulation of LTα1β2 with increased LTßR engagement, and thereby establishes a
positive feedback loop.
(C) Formation of splenic B cell follicles (left) is mediated through CXCR5 signaling through its ligand CXCL13, which upregulates LTα1β2
expression on B cells. These activated B cells trigger LTßR on stromal cells thereby upregulating CXCL13, again generating a positive
feedback loop. (right) At neonatal stage CD3−CD4+CD45+ cells are the predominant source of LTα1β2 expression and respond to CXCL13,
whereas B cells do not at this stage of development. CD3−CD4+CD45+ cells induce chemokine expression in the developing lymph nodes
thereby initiating organization of nodal microenvironment (e.g., B cell follicles) (Cupedo et al., 2004b).
(D and E) Peripheral infection with the prion agent (e.g., orally or intraperitoneally). The prion agent might (with the help of the complement
system) be captured and transported by B cells, dendritic or other cells via the afferent lymph or blood system into secondary lymphoid
organs, where it accumulates in germinal centers. There, it is mainly replicated by CD35+/FDC-M1+/PrPC high mature FDCs, leading to neuroin-
vasion and terminal disease of the host.
(F) Pharmacological blockade of LTßR signaling via administration of soluble dimeric LTßR-Ig profoundly impairs peripheral prion pathogene-
sis (Mabbott et al., 2000; Montrasio et al., 2000).
(G) Passive immunization with PrP-specific antibodies after prion exposure delays disease and markedly increased the incubation period
compared with nonimmunized mice (White et al., 2003).tion, failed to alter the incubation period of the disease
(Fraser and Farquhar, 1987). These findings suggested
that scrapie replication or accumulation in the LRS de-
pends on radioresistant, postmitotic cells localized
within the stroma. However, these experiments did not
address the exact cellular and molecular preconditions
for prion transport from their entry portals to the periph-
eral sites of replication, and transmigration of infectivity
into the CNS.
Interestingly, PrPC itself is involved in transporting
prion infectivity from peripheral sites to the CNS: titra-
tion experiments indicate that adoptive transfer of wild-
type (wt) bone marrow into Prnpo/o mice reconstitutes
the capability of the spleen to accumulate prions of the
RML strain (Blättler et al., 1997; Kaeser et al., 2001).
These results were taken to suggest that PrPC-express-
ing hematopoietic cells transport prions from the entry
site to the LRS, accumulating and replicating prions.
Further, reconstitution experiments with wt mice into
Prnpo/o mice were insufficient to restore neuroinvasion.
Therefore, hematopoietic cells (e.g., B and T cells and
dendritic cells) facilitate the transport prions from the
peripheral entry site to secondary lymphoid organs,
where prions accumulate and/or replicate. However,
the elemental compartment for prion neuroinvasion ap-
pears to be nonhematopoietic, because it cannot be
adopted by bone marrow reconstitution (Blättler et al.,
1997; Kaeser et al., 2001; Klein et al., 1997).
In conclusion, after peripheral exposure—may this be
by ingestion or by peripheral infection—prion patho-
genesis is a dynamic process that can be split spatially
and temporally into: (1) infection and peripheral replica-
tion, (2) transmigration from the periphery to the central
nervous system (CNS), and (3) progressive neurode-
generation leading to death.
A Chain of Events Leading to Brain
Which cells and which molecules, besides PrPC, are
needed for efficient prion replication in the LRS and
subsequent neuroinvasion? There is no doubt that B
cells are of crucial importance for peripheral prion
spread and neuroinvasion (Klein et al., 1997). However,
PrPC expression on B cells is not required for prion neu-
roinvasion (Klein et al., 1998; Montrasio et al., 2001).
The latter result, combined with the fact that a stromalsion, indicates that B cells themselves are unlikely to
represent a major replicative compartment for prions.
Instead, the apparent requirement for B lymphocytes in
peripheral pathogenesis is more likely to derive from
indirect effects, such as the expression of cytokines. A
prime candidate mediator is the proinflammatory cy-
tokine lymphotoxin α (LTα), which was originally recog-
nized for its cytotoxic effects on normal and trans-
formed cells in vitro and therefore termed cytotoxin
(Ruddle and Waksman, 1967; Ruddle and Waksman,
1968).
Today, lymphotoxins (LTs) are known to belong to a
growing family of structurally related cytokines, the TNF
superfamily, along with various ligands such as TNF,
CD40L, LIGHT, FasL, BAFF, and their corresponding re-
ceptors (Fu and Chaplin, 1999; Locksley et al., 2001).
Members of the TNF superfamily serve pleiotropic
functions in proliferation, costimulation, regulation of
the immune response, apoptosis of particular cell lin-
eages, control of lymphoid organogenesis, as well as
maintenance of secondary lymphoid microarchitecture
(Fu and Chaplin, 1999; Fu et al., 1997; Locksley et al.,
2001). LTα, LTβ, and TNF share structural and functional
similarities, including their assembly into functionally
active homotrimers and/or heteotrimers. Interestingly,
the genes encoding for LTα, LTβ, and TNF are also
found in close proximity to each other, within the major
histocompatibilty locus (Muller et al., 1987).
LTs are mainly expressed on the surface of B cells
and activated T cells and exist as heterotrimeric LTα1β2
or LTα2β1, both triggering LTβ receptor (LTßR), ex-
pressed by stromal cells (Browning et al., 1993). In ad-
dition to T and B cells, LT can be produced by recently
characterized CD3−CD4+CXCR5+ precursor cells, which
are essential for the development of lymph nodes and
Peyer’s Patches (PP) (Mebius et al., 1997; Ware et al.,
1992) (Figure 1). The cellular and molecular require-
ments for the establishment of lymph nodes and terti-
ary structures are remarkably similar, and hyperacti-
vated lymphocytes can fulfill the role of lymphoid tissue
inducers during inflammatory responses (Cupedo et
al., 2004a).
Although the participation of LTβ leads to membrane
anchoring of the ternary complex, LTα can also be
secreted as soluble LTα3 homotrimer, signaling via
TNFR1, TNFR2, and most likely the herpes simplex
Immunity
1481993). LTα mRNA expression is inducible in B cells, L
pwhereas LTβ mRNA is constitutively produced: the pro-
ductive generation of surface LTβ depends on the for- a
smation of complexes with LTα (Browning et al., 1993;
Worm and Geha, 1994). Surface LT expression en- g
lhances production of homeostatic chemokines by stro-
mal cells within the spleen and other secondary lym-
tphoid organs (Ngo et al., 1999; Shakhov et al., 2000).
Homeostatic chemokines (e.g., CXCL13), expressed by t
tLT responsive cells (e.g., FDCs), upregulate surface ex-
pression of the LT complex on B cells (Ansel et al., t
c2000), providing a positive feedback loop essential for
the organization of lymphoid follicles and for the gener- F
tation of tertiary follicles in nonlymphoid organs. More-
over, ectopic expression of LTα in kidney and pancreas M
rwas shown to induce chronic inflammation with charac-
teristics of organized lymphoid tissue (Kratz et al., i
m1996).
M
fLymphoid Microarchitecture and Prion Replication
tWithin lymphoid organs, B cells localize to morphologi-
ccally and functionally distinct compartments, depend-
hing on the status of their development. A majority of B
tcells can be either found in the splenic white pulp or in
FB cell zones of Peyer’s patches (PP) and lymph nodes
p(LN). There, B cells not only initiate and control immune
iresponses but also provide LT, TNF, and other factors,
contributing to maturation and maintenance of preex-
isting mature FDCs and microarchitecture of secondary F
Tlymphoid organs (Cyster et al., 1999; Fu and Chaplin,
1999). The histogenesis of FDCs is still quite unclear, A
ibut there is a near consensus that they are of stromal
origin and express high levels of PrPC. The impairment e
sof signals provided by B cells leads to the failure of
maintenance of mature FDCs, to abrogation of germinal 2
scenters, and to a generally disorganized microarchitec-
ture, as documented in LTα−/−, LTβ−/−, LTβR−/−, and t
mTNFR1−/− mice (Bluethmann et al., 1994; De Togni et al.,
1994; Futterer et al., 1998; Koni et al., 1997). Inhibition p
aof the LTßR pathway in mice and nonhuman primates
by treatment with LTβR-immunoglobulin fusion protein P
i(LTβßR-Ig) leads to the disappearance and dedifferenti-
ation of mature, functional FDCs, in spleen, in lymph t
tnodes, and also in inflammatory foci containing tertiary
follicles (e.g., models of lupus, nephritis, or pancreatitis) t
2(Gommerman and Browning, 2003; Gommerman et al.,
2002; Mackay and Browning, 1998).
fBecause FDCs accumulate PrPSc after scrapie infec-
tion (Kitamoto et al., 1991) and prion replication in u
bspleen depends on PrPC-expressing FDCs (Brown et al.,
1999), it appeared worthwhile to investigate whether de- m
bpletion of FDCs inhibits prion pathogenesis. Indeed,
mice devoid of FDCs and lacking an organized micro- t
earchitecture (e.g., LTα−/−, LTβ−/−, and LTßR−/− mice)
showed highly reduced efficiency of prion replication p
cafter peripheral exposure (Prinz et al., 2002).
Encouragingly, even pharmacological blockade of i
dLTβR signaling via administration of soluble dimeric
lymphotoxin β receptor (LTβR-Ig) was found to signifi- l
acantly impair peripheral prion pathogenesis (Mabbott
et al., 2000; Montrasio et al., 2000). In a recent series r
cof experiments aimed at determining dose-response
relationships, we found that treatment of mice with eTβR-Ig for 1 week before a relatively low-dose i.p. ex-
osure to prions and then every week for only 2 weeks
fter inoculation completely protected mice from
crapie, whereas control injection of pooled immuno-
lobulin did not prevent disease (M.H. and A.A., unpub-
ished data, and Figure 1F).
FDCs are bifunctional cells: they support the forma-
ion and maintenance of the lymphoid microarchitec-
ure but also play a role in antigen trapping, in the cap-
uring of immune complexes by Fcγ receptors, and in
he binding of opsonized antigens to the CD21/CD35
omplement receptors. For this reason, functional
DCs are believed to express CD21/CD35 in addition
o their positivity for “FDC-specific” markers (e.g., FDC-
1). These facts made it interesting to investigate the
ole of the complement cascade in prion diseases. Two
ndependent studies demonstrated that the comple-
ent system is highly relevant to prion pathogenesis.
ice genetically engineered to lack complement
actors (Klein et al., 2001) as well as mice depleted for
he C3 complement component by administration of
obra venom factor (Mabbott et al., 2001) exhibited en-
anced resistance to peripheral prion inoculation. In fu-
ure experiments, it will be exciting to study whether
DC-associated complement receptors have a role in
romoting the efficiency and transport of prion infectiv-
ty in extraneural compartments.
rom the Periphery into the Lymphoid System:
he First Portal of Entry
n early rise in prion infectivity is observed in the distal
leum of orally infected organisms. This applies to sev-
ral species but was most extensively investigated in
heep and deer (Heggebo et al., 2003; Sigurdson et al.,
002). Western blot analyses and bioassays have
hown that PPs accumulate PrPSc and contain high ti-
ers of prion infectivity. Similarly, after administration of
ouse-adapted scrapie prions (RML strain) mice ex-
erience a surge in intestinal prion infectivity as early
s a few days after inoculation (Mabbott et al., 2003;
rinz et al., 2003c). Immune cells are crucially involved
n the process of neuroinvasion after oral administra-
ion: mature FDCs, located in PPs, may be critical for
he transmission of scrapie from the gastrointestinal
ract (Aguzzi, 2003; Mabbott et al., 2003; Prinz et al.,
003c).
However, the cellular basis for prion transmigration
rom the gut into the lymphoid system is still poorly
nderstood. Membranous epithelial cells (M cells) are
elieved to be the key sites of antigen sampling for the
ucosal-associated lymphoid system (MALT) and have
een recognized as major ports of entry for enteric pa-
hogens in the gut via transepithelial transport (Neutra
t al., 1996). Interestingly, maturation of M cells is de-
endent on signals transmitted by intraepithelial B
ells. Efficient in vitro systems have been developed
n which epithelial cells can be instructed to undergo
ifferentiation to cells that resemble M cells by morpho-
ogical and functional physiological criteria (Kerneis et
l., 1997). This led to the presumption that M cells may
epresent a site of prion entry—a fact substantiated in
oculture models (Heppner et al., 2001a)—but not yet
stablished in vivo.
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Even though the results discussed above clearly show
that FDCs are of great importance for peripheral prion
pathogenesis, it is counterintuitive that a sessile cell of
stromal origin, stably localized in germinal centers of
the LRS, should be involved in transporting prions to
the CNS. In the past, many studies focused on the tem-
poral and spatial dynamics of neuroinvasion, suggest-
ing that the autonomic nervous system might be re-
sponsible for transport from lymphoid organs to the
CNS (Clarke and Kimberlin, 1984; Cole and Kimberlin,
1985; McBride and Beekes, 1999). The innervation
pattern of lymphoid organs is primarily sympathetic
(Felten et al., 1988). Sympathectomy delays the onset
of scrapie upon i.p. inoculation of the infectious agent,
whereas sympathetic hyperinnervation enhances sple-
nic prion replication and neuroinvasion, suggesting that
innervation of secondary lymphoid organs is the rate
limiting step to neuroinvasion (Glatzel et al., 2001).
However, there is no direct physical synapse between
FDCs and sympathetic nerve endings (Heinen et al.,
1995).
There is strong evidence that the distance between
FDCs and splenic nerves affects the velocity of neu-
roinvasion (Prinz et al., 2003a). FDC positioning was
manipulated by ablation of the CXCR5 chemokine re-
ceptor, which directs lymphocytes toward specific
microcompartments (Forster et al., 1996). In this model
the distance between germinal center-associated FDCs
and nerve endings was greatly reduced (Forster et al.,
1996; Prinz et al., 2003a). CXCR5 deficiency did not af-
fect any aspect of prion pathogenesis within the CNS.
However, although after peripheral administration of
high doses of prion inocula velocity of pathogenesis
was similar in CXCR5−/− and wild-type mice, delivery of
smaller inocula resulted in a dose-dependent increase
in incubation periods in wt mice. Measurement of the
kinetics of prion infectivity titers in the thoracic spinal
cord showed that increased velocity of prion entry into
the CNS in CXCR5−/− mice is due to repositioning of
FDCs in juxtaposition with highly innervated, splenic ar-
terioles. This was validated by prolongation of incuba-
tion periods in CXCR5−/− mice depleted for mature
FDCs.
It remains to be determined whether increased veloc-
ity of neuroinvasion results from passive diffusion of
prions or whether, alternatively, mobile cells (e.g., ger-
minal center B cells) are involved in an active process.
This study also raises the possibility that the spread of
infection to peripheral nerves occurs more rapidly in
lymphoid tissues, where FDCs are in near proximity to
nerves than in the spleen of wt mice, such as PP
(Beekes and McBride, 2000; Mabbott and Bruce, 2003).
Only recently was it shown that FDCs are crucial to dis-
ease progression for only a very short time window af-
ter oral scrapie challenge: if FDCs are depleted in this
time window, mice will not succumb to scrapie (Mab-
bott and Bruce, 2003; Mabbott et al., 2003). Because
lymphoid infectivity is found in most prion diseases and
proinflammatory cytokines and immune cells are in-
volved in lymphoid prion replication (Brown et al., 1999;
Kitamoto et al., 1991; Mabbott et al., 2002; Montrasio
et al., 2000; Prinz et al., 2003a, 2002), it seemed reason-
able to test whether chronic inflammatory conditionsaffect prion pathogenesis. We therefore administered
prions to mice with various naturally occurring or trans-
genetically induced inflammatory or autoimmune dis-
eases of kidney, pancreas, or liver. In each of these par-
adigms, chronic inflammation enabled prion replication
in otherwise prion-free organs, and inflammatory foci
consistently correlated with LT upregulation and ectopic
induction of PrPC-expressing FDC-M1+ cells (Heiken-
walder et al., 2005). It is therefore plausible that chronic
inflammatory conditions may act as modifiers of natural
and iatrogenic prion transmission by expanding the tis-
sue distribution of prions. Interestingly, inflamed organs
of prion-inoculated mice lacking LTα or LTβR were de-
void of PrPSc and prion infectivity. This indicated that
inflammation and prion replication competence are hi-
erarchically linked by LT signaling.
It is important to note that as recently shown, den-
dritic cells resembling mobile cells of the immune sys-
tem can act as a cellular bridge between the gut lumen
and the lymphoid TSE replicative machinery (Huang et
al., 2002). As a further extension of this, one could pos-
tulate that DCs could therefore also be a cargo ma-
chinery for directed transport from the site of prion rep-
lication to peripheral nerves within lymphoid organs,
thereby enabling neuroinvasion. Moreover, other mobile
“elements” (e.g., exosoms; budding endogenous viruses)
could serve as transport vehicles of prion infectivity.
Additionally, it was shown that splenic CD11c+ cells
isolated from scrapie-infected donors and injected in-
travenously into RAG1−/− mice induced scrapie without
accumulation of prions in the spleen (Aucouturier et
al., 2001).
Idiosyncrasies of the Proposed Model
for Neuroinvasion
The findings described above have led us and others
to hypothesize a linear model of prion dissemination in
which prions accumulate primarily in the FDCs, get to
the neighboring nervous endings, and from there pro-
gress in a neuroretrograde way up to the CNS.
Although this scenario is supported by good experi-
mental evidence, it shouldn’t go unmentioned that it
does not quite explain how prions reach FDC sites at
first hand, how they disseminate secondarily through-
out the lymphoid system, and how they travel from
FDCs to nerve endings. Each of these questions will
need to be addressed in order to achieve a thorough
understanding of peripheral prion pathogenesis.
Most importantly, the accumulating evidence of
blood-borne infectivity in various forms of TSE (Hous-
ton et al., 2000; Llewelyn et al., 2004; Peden et al., 2004)
implies that mobile cells participate to the spreading of
the infection. The nature of such mobile cells is most
likely hematopoietic, as wt bone marrow restores prion
replication in Prnpo/o spleens (Blättler et al., 1997). Lym-
phocytes may well contribute to the prion load in blood,
as they were shown to acquire infectivity when residing
in lymphoid organs (Raeber et al., 1999). If so, the cru-
cial role of B cells for peripheral prion pathogenesis
(Klein et al., 1997) may transcend their function as lym-
photoxin producers. Increasing evidence suggests that
dendritic cells may also represent a candidate “prion
transporter” (Aguzzi, 2001; Aucouturier et al., 2001; Hu-
Immunity
150ang et al., 2002). Finally, micellar membrane compo- t
rnents, be they actively extruded from prion-infected
cells membranes (“exosomes”) or simply representing d
(residues of dead cells, may represent a further vehicle
of prion spread (Fevrier et al., 2004). t
m
2The Fight against the Prion
vOne may wonder how to translate the impressive body
sof accrued knowledge of the molecular underpinnings
hof prion neuroinvasion into practical applications. As in
aany other infectious disease, three major long-tems
rgoals need to be achieved: (1) refined, sensitive prion
Odiagnostics, (2) methods for postexposure prophylaxis
iof prion infections, and (3) efficacious therapeutic inter-
pventions.
iThe realization that the agent is present in lymphoid
torgans has indeed paved the way to a variety of lowly
invasive diagnostic methods. Whereas 10 years ago the
mdiagnosis of Creutzfeldt-Jakob disease could only be
tconfirmed ante mortem by brain biopsy, it is now pos-
tsible to unambiguously detect PrPSc in tonsils and/or
hspleen of patients with vCJD (Hill et al., 1997) and sCJD
a(Glatzel et al., 2003). However, although a tonsil biopsy
pis preferable to a brain biopsy, neither method is suit-
pable to mass screening, which would be most desir-
mable; e.g., for identifying prion-tainted blood units. Un-
tfortunately, the diagnostic holy grail of recognizing
gprion infection by testing blood remains elusive. Early
tclaims of identification of prions in urine (Shaked et al.,
m2001) have stirred considerable interest but were sub-
tsequently proven to derive from trivial artifacts (Furu-
Ckawa et al., 2004; Serban et al., 2004). However, the
scientific, economic, and public health interest in prion
diagnostics on body fluid is red hot, and we have little T
Sdoubt that the accrued knowledge on peripheral prion
pathogenesis will pave the way to advances in this c
afield.
There continue to be no efficacious therapeutic options o
ragainst prion diseases. Various drugs were screened for
possible prion-curing properties in vitro. Substances in- (
wcluded Congo red (Caughey and Race, 1992), ampho-
tericin B, anthracyclins (Tagliavini et al., 1997), sulfated l
ipolyanions (Caughey and Raymond, 1993), porphyrins
(Priola et al., 2000), branched polyamines (Supattapone a
2et al., 2001), “β-sheet breakers” (Soto et al., 2000), the
spice curcumin (Caughey et al., 2003), and recently l
geven siRNAs downregulating PrPC (Daude et al., 2003),
as well as dominant-negative mutants of PrPC (Crozet m
met al., 2004). Most of these molecules exert their biolog-
ical effects by directly or indirectly interfering with con- a
gversion of PrPC to PrPSc, thereby also aiding clearance
of PrPSc. Yet none of these compounds have proved e
very effective for actual therapy (Aguzzi et al., 2004).
After results obtained in mice, cytidyl-guanyl oligo- e
cdeoxynucleotides (CpG-ODN), which stimulate the in-
nate immune system via Toll-like receptor 9 (TLR9) sig- a
vnaling receptors on a variety of immune cells, have
been proposed as a feasible treatment regimen to delay t
Pprion disease (Sethi et al., 2002). It was shown that prion
disease incubation period was extended in mice re- m
apeatedly treated with CpG-ODN for 20 days, and it was
speculated that stimulation of innate immunity accounts S
cfor this apparent antiprion effect, possibly through induc-ion of anti-PrP antibodies. However, this is difficult to
econcile with several studies that indicate that immune
eficiencies of various sorts inhibit prion pathogenesis
Frigg et al., 1999; Klein et al., 1997, 1998, 2001). In addi-
ion, prion pathogenesis is unhampered in MyD88−/−
ice, in which TLR9 signaling is impaired (Prinz et al.,
003b). In fact, repeated CpG-ODN treatment has se-
ere side effects, ranging from lymphoid follicle de-
truction and impaired antibody class switch to ascites,
epatotoxicity, and thrombocytopenia (Heikenwalder et
l., 2004). Besides, exhaustive studies have failed to
eveal the induction of anti-PrP antibodies in CpG-
DN-treated mice (Heikenwalder et al., 2004; Polymen-
dou et al., 2004). It is therefore more likely that the anti-
rion effects of repeated CpG-ODN treatment arise via
ndiscriminate and undesired destruction of lymphoid
issue.
From all of the above, it would appear that LTβR-Ig
ay presently represent the only antiprion compound
hat may be realistically exploited for postexposure
reatment of humans. As an important qualification,
owever, treatment with LTβR-Ig could be considered
s possible postexposure prophylaxis at early time
oints, and only in those rare cases in which prion ex-
osure is well documented and punctual. These cases
ight include recipients of blood transfusions from pa-
ients with CJD, and possibly pathologists, neurolo-
ists, neurosurgeons, researchers, and technicians af-
er accidental CJD injection. In contrast, the presumed
echanism of action of LTβR-Ig allows us to predict
hat it will not provide any relief to patients with overt
JD for whom neural entry has already taken place.
he Quest for a Prion Vaccine
trategies for immunization against prion diseases
ontinue to represent a field of intense efforts (Aguzzi
nd Sigurdson, 2004). Mice transgenic for the µ-chain
f a PrP-specific antibody (6H4µ mice) were found to
esist prion disease after exposure by a peripheral route
Heppner et al., 2001b). Of course, 6H4µ mice are not
t, and this may represent a caveat (Mallucci and Col-
inge, 2005). However, 6H4 mice mount fully protective
mmune responses against vesicular stomatitis virus
nd lymphocytic choriomeningitis virus (Heppner et al.,
001b). Also, they have normal lymphocyte subpopu-
ations in thymus, spleen, and blood; normal immuno-
lobulin levels; and normal splenic and lymph nodal
icroarchitecture. By contrast, expression of a nonim-
unoreactive transgenic heavy chain did not afford
ntiprion protection. We find it therefore difficult to ar-
ue that antiprion protection came about by anything
lse than anti-PrPC immunity in this mouse model.
Prion-specific antibodies were not shown to be gen-
rated during the course of prion infections, but artifi-
ial induction of humoral immune responses to PrPC
nd/or PrPSc might be protective. However, efficient
accination against the prion protein has proven ex-
remely challenging. First, wt mice are highly tolerant to
rP as an immunogen, because PrPC is expressed al-
ost ubiquitously and found at the surface of both B
nd T cells (Cashman et al., 1990; Manson et al., 1992).
econd, it was generally thought that antibodies spe-
ific for PrPC might lead to severe systemic immune-
Review
151mediated diseases, because PrP is expressed by many
cell types outside the CNS. Third, PrP-specific anti-
bodies would be unlikely to cross the blood brain bar-
rier in therapeutic concentrations.
In parallel, many other publications addressed prion
immunoprophylaxis, both in vitro and in vivo (Enari et
al., 2001; Peretz et al., 2001). Additionally, passive im-
munization with PrP-specific antibodies after prion ex-
posure delayed disease and markedly increased the in-
cubation period compared with nonimmunized mice
(White et al., 2003) (Figure 1G). However, so far active
immunization efforts have not succeeded in eliciting
protective PrP-specific antibodies, most likely due to
immune tolerance to self-antigens (Polymenidou et al.,
2004). Recently, a transgenic mouse was developed
that expresses full-length mouse PrP rendered soluble
and dimeric by fusion with the Fc portion of human
IgG1 (known as PrP-Fc2) (Meier et al., 2003).
After prion inoculation, these mice were surprisingly
found to exhibit delayed onset of disease after intrace-
rebral or intraperitoneal prion inoculation, which was
equivalent to an w100-fold reduction in titer of the
prion-infected inoculum (Meier et al., 2003). The PrP-
Fc2 was not converted to a prion disease-causing iso-
form. This remarkable antiprion effect occurred in two
distinct lines of PrP-Fc2-expressing transgenic mice.
Therefore, it seems that PrP-Fc2 effectively antagonizes
prion accumulation in the spleen and brain.
If one were to translate these findings into a thera-
peutical concept, the crucial question would be
whether PrP-Fc2 needs to be produced within the cell
to be protected or whether it can act from outside
(“non-cell-autonomously”). Preliminary data (N. Gen-
oud and A.A., unpublished data) appear to suggest that
the antiprion effect of PrP-Fc2 is not necessarily cell
autonomous. If this finding were to be robustly con-
firmed in a few independent paradigms, one might en-
visage that injection of PrP-Fc2 protein, or gene transfer
of PrP-Fc2 via viral vectors, could have therapeutic po-
tential.
Conclusions
Prion immunology is not an entirely novel branch of sci-
ence. The first seminal experiments identifying prion
replication in lymphoid organs were performed by the
prion research community of Edinburgh in the 1960s. In
those days, the term “prion” had not yet been coined
and the animal bioassay was the only available analyti-
cal tool. Considering the technical limitation of that
time, it is amazing how clairvoyant the pioneers of prion
immunology, including Hugh Fraser and Richard Kim-
berlin, have been. Many molecular experiments that
were performed with transgenic and knockout mice in
recent days have essentially confirmed several of the
observations and predictions that were put forward 30
years ago. Spurred not only by the BSE disaster and
by public health needs, but also by the fundamental
biological challenges posed by the “prion puzzle,” the
pace of prion research has picked up considerably in
the meantime. Much of the mechanics of prion lym-
phoinvasion and neuroinvasion has been elucidated in
considerable molecular detail. In the next phase, it will
be exciting to see these theoretical advances beingtranslated into medical progress toward the establish-
ment of efficient diagnostic, prophylactic, and thera-
peutic antiprion regimens.
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